Medeon Biodesign, Inc. announced a private placement of 35,000,000 common shares on February 29, 2024. The transaction will include participation from new investors Center Laboratories, Inc. and Medeon, Inc. and individual investors Yue-Teh Jang, Jung-Chin Lin, Chih-Hsiung Wu, Hong-Jen Chang, Hsin-Yuan Fang, Chi-Hang Yang, Chia-Ying Ma, Jerome Shen, Jien-Wei Yeh, Albert Weng, Greta Chang, Jenny Chen, Pei Chen, Janice Chang/ and Tori Lin and institutional investors Yue-Teh Jang for 100% stake, Li Rong Technology Co., Ltd. for 8.70% stake, Royal Food Co., Ltd. for 5.99% stake, Jason Technology Co., Ltd. for 2.37% stake, Farglory Life Insurance Inc. for 1.63% stake, You De Investment Consulting Co., Ltd. for 1.38% stake, MasterLink Securities Corp. for 1.07% stake, Mumozi Inc. for 1.03% stake, Yong Lian Co., Ltd. for 1% stake, Wechen Co.

Ltd. for 0.89% stake and JPMorgan Chase Bank, National Association (Taipei Branch) for 0.86% stake. The transaction has ben approved by the shareholders of the company.